Introduction Clinicians need to know whether lumbosacral radiculopathy (LRS) can be attributed to work. Therefore the association between work-related risk factors and clinically assessed LRS has to ...

The lumbosacral plexus is formed by the ventral ... Apart from tumors, other causes of sciatica-type pain in the absence of radiculopathy due to herniated nucleus pulposus include the following ...

It cites an uncertain benefit and risk profile of suzetrigine in lumbosacral radiculopathy, and doubts on its commercial potential in acute paid ahead of the January 30, 2025, FDA action date for ...

He was subsequently commenced on oral valacilovir and made significant recovery. This report aims to highlight the diagnostic dilemma between cervical radiculopathy secondary to spondylosis and zoster ...

An archived webcast will be available on the company's website. About the Phase 2 Suzetrigine Lumbosacral Radiculopathy (LSR) Study This phase 2, 12-week, randomized, double-blind, placebo ...

Vertex Pharmaceuticals shares sank Thursday after the company reported mixed results in a Phase 2 drug trial to treat lumbosacral radiculopathy (LSR), which causes leg and back pain. The company ...

Vertex Pharmaceuticals’ (NASDAQ:VRTX) investigational non-opioid drug, suzetrigine, has met the primary endpoint in a mid-stage study in people with painful lumbosacral radiculopathy (LSR).

highly selective NaV1.8 pain signal inhibitor in people with painful lumbosacral radiculopathy (LSR). The study met its primary endpoint with statistically significant and clinically meaningful ...

BOSTON, December 19, 2024--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from its Phase 2 study of suzetrigine, an investigational, oral, highly selective ...